# Study of VX-770 on Desipramine

> **NCT01153542** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 24 (estimated)

## Conditions studied

- In Development for Cystic Fibrosis

## Interventions

- **DRUG:** VX-770
- **DRUG:** VX-770

## Key facts

- **NCT ID:** NCT01153542
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153542, "Study of VX-770 on Desipramine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01153542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*